The Medical Advisor

OneDayMD • The Medical Advisor A single starting point for exploring OneDayMD's health, wellness, longevity, nutrition, cancer, metabolic medicine, emerging therapies and digital-health research. Quick Answer OneDayMD is an independent health-information and research-synthesis platform covering conventional medicine, integrative health, longevity, nutrition, supplements, metabolic medicine, cancer research, emerging therapies and digital health. This Master Guide is the site's central navigation page: use it to find the right topic hub, then move from a broad guide to the specific evidence, study, therapy, supplement, condition or research question you are investigating. On this page Start Here · Core Health Hubs · Cancer & Oncology · Nutrition & Supplements · Longevity · GLP-1 & Metabolic Health · DMSO ·...

TL;DR  Best weight loss:  Mounjaro Best overall balance:  Wegovy Safest long-term data:  Semaglutide class Most overlooked truth:  benefits extend beyond weight Introduction: The GLP-1 Era Has Changed Medicine Over the past decade, a new class of medications— GLP-1 receptor agonists and incretin-based therapies —has fundamentally reshaped how we treat: Obesity Type 2 diabetes Cardiovascular risk Drugs like Ozempic, Wegovy, Mounjaro, and Trulicity are no longer niche therapies. They are now: Among the most prescribed metabolic drugs globally Central to what some call the “Ozempic economy” Positioned as potential lifespan-extending interventions But with rapid adoption comes confusion—and increasingly polarized narratives: One side: “These drugs are miracle breakthroughs” The other: “We don’t fully understand them—are they risky?” The truth sits in between. This guide cuts through both hype and fear to answer one question: Which GLP-1 drug is best—and what are th...

Medically & Technically Reviewed by: OneDayMD Editorial Team | Originally Published: August 9, 2026 | Updated: September 2026 Quick Answer There is no single "best" smart glasses for visual impairment in 2026 — the right pick depends on how much usable vision remains. For low vision (residual central vision from macular degeneration, diabetic retinopathy, or Stargardt disease), medical-grade enhancers like eSight Go ($4,950) or Acesight VR digitally magnify and boost contrast. For blind or near-blind users, AI-interpretation glasses like Envision Glasses ($2,499), Ally Solos (from $399), or a clip-on OrCam MyEye 3 Pro (remaining dealer stock, $3,689–$4,490) read text and describe scenes aloud. The cheapest mainstream option is Meta's expanding AI-glasses lineup — Ray-Ban Meta, Meta Glasses (Adventurer/Fury), and Meta Glasses by Kylie — starting at $299, which isn't purpose-built for accessibility but has become a popular everyday alternative thanks t...